Stockreport

Outlook Therapeutics Completes Patient Enrollment for NORSE 2 Study of ONS-5010 / LYTENAVA™ (bevacizumab-vikg)

Outlook Therapeutics, Inc.  (OTLK) 
Last outlook therapeutics, inc. earnings: 2/14 08:00 am Check Earnings Report
PDF Pivotal NORSE 2 safety and efficacy data expected to be reported in the third calendar quarter of 2021  ONS-5010 / LYTENAVA™ (bevacizumab-vikg) has the potential to be t [Read more]